Type: Second-generation C3 inhibitor designed to control the complement cascade centrally at C3. According to Apellis, APL-9 could treat a range of diseases caused by excessive or uncontrolled activation of complement.
Status: Apellis said May 28 that it initiated the Phase I/II APL9-COV-201 trial (NCT04402060), designed to assess of APL-9 in COVID-19 patients with respiratory failure including acute respiratory distress syndrome (ARDS). The randomized, multi-center, controlled study is expected to enroll 66 hospitalized patients with COVID-19 and respiratory failure who require oxygen supplementation or mechanical ventilation.
The trial’s primary objective is to evaluate the safety of APL-9 as an add-on to the current standard of care. Secondary objectives include evaluating length of stay in the hospital, overall survival, time on oxygen therapy or mechanical ventilation, and markers of complement activation, organ failure, and blood clotting.
“ARDS and harmful blood clots are associated with mortality in COVID-19, and we believe that dysregulation of complement plays a key role in both of these conditions,” Apellis’ chief innovation officer Lukas Scheibler, PhD, said in a statement.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: